Skip to content
IconOVir
  • About Us
    • Meet our Team
    • Board of Directors
    • Scientific Advisory Board
  • News/Events
    • Press Releases
    • Posters/Publications
  • Careers
  • Contact
Menu
  • About Us
    • Meet our Team
    • Board of Directors
    • Scientific Advisory Board
  • News/Events
    • Press Releases
    • Posters/Publications
  • Careers
  • Contact

Day: July 11, 2023

IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical Trial of its Lead Product Candidate, ICVB-1042

— ICVB-1042 is an oncolytic adenovirus for the treatment of advanced solid tumors —— Initial safety data expected in 2H 2023, followed by proof-of-concept data in 2024 —  SAN DIEGO, CA., July 11, 2023 – IconOVir Bio, Inc. (IconOVir), a clinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the […]

CORPORATE OFFICE

IconOVir Bio
4570 Executive Drive
Suite 350
San Diego, CA 92121

 

Partnering Inquiries
info@iconovir.com
MEDIA INQUIRIES AT
media@iconovir.com
Linkedin
Contact Us
CORPORATE OFFICE

IconOVir Bio
4570 Executive Drive
Suite 350
San Diego, CA 92121

 

Partnering Inquiries
info@iconovir.com
MEDIA INQUIRIES AT
media@iconovir.com
Linkedin
Contact Us
CORPORATE OFFICE

IconOVir Bio
4570 Executive Drive
Suite 350
San Diego, CA 92121

 

Partnering Inquiries
info@iconovir.com
MEDIA INQUIRIES AT
media@iconovir.com
Linkedin
Contact Us
©2023 IconOVir Bio
©2022 IconOVir Bio